Cancer‑associated fibroblast‑induced M2‑polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor‑1 pathway.
Cancer-Associated Fibroblasts
/ cytology
Carcinoma, Hepatocellular
/ metabolism
Cell Communication
Cell Line, Tumor
Cell Movement
Cell Polarity
Cell Proliferation
Coculture Techniques
Disease Progression
Gene Expression Regulation, Neoplastic
Humans
Liver Neoplasms
/ metabolism
Macrophage Activation
Plasminogen Activator Inhibitor 1
/ metabolism
Prognosis
Signal Transduction
THP-1 Cells
Tumor Microenvironment
Tumor-Associated Macrophages
/ cytology
Up-Regulation
cancer‑associated fibroblasts
epithelial‑mesenchymal transition
hepatocellular carcinoma
plasminogen activator inhibitor‑1
tumor‑associated macrophages
Journal
International journal of oncology
ISSN: 1791-2423
Titre abrégé: Int J Oncol
Pays: Greece
ID NLM: 9306042
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
28
12
2020
accepted:
22
04
2021
entrez:
1
7
2021
pubmed:
2
7
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
Targeting the tumor stroma is an important strategy in cancer treatment. Cancer‑associated fibroblasts (CAFs) and tumor‑associated macrophages (TAMs) are two main components in the tumor microenvironment (TME) in hepatocellular carcinoma (HCC), which can promote tumor progression. Plasminogen activator inhibitor‑1 (PAI‑1) upregulation in HCC is predictive of unfavorable tumor behavior and prognosis. However, the crosstalk between cancer cells, TAMs and CAFs, and the functions of PAI‑1 in HCC remain to be fully investigated. In the present study, macrophage polarization and key paracrine factors were assessed during their interactions with CAFs and cancer cells. Cell proliferation, wound healing and Transwell and Matrigel assays were used to investigate the malignant behavior of HCC cells
Identifiants
pubmed: 34195849
doi: 10.3892/ijo.2021.5239
pii: 59
pmc: PMC8253588
doi:
pii:
Substances chimiques
Plasminogen Activator Inhibitor 1
0
SERPINE1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Dig Dis Sci. 2019 Oct;64(10):2843-2853
pubmed: 30949902
Cancer Biomark. 2020;27(3):285-293
pubmed: 31640087
Mol Cancer Res. 2014 Mar;12(3):322-34
pubmed: 24464915
Exp Cell Res. 2019 May 15;378(2):131-138
pubmed: 30857971
Hepatology. 2018 May;67(5):1872-1889
pubmed: 29171040
Lab Invest. 2019 Jun;99(6):777-792
pubmed: 30683902
Exp Cell Res. 2020 Jun 1;391(1):111987
pubmed: 32240661
Science. 2014 May 23;344(6186):921-5
pubmed: 24812208
Nat Commun. 2016 Oct 11;7:13050
pubmed: 27725631
Cancer Lett. 2020 Oct 28;491:132-145
pubmed: 32829009
Nat Commun. 2018 Feb 8;9(1):559
pubmed: 29422647
Mol Cancer Ther. 2013 Dec;12(12):2697-708
pubmed: 24072883
Oncogene. 2014 May 8;33(19):2423-31
pubmed: 23728338
Anticancer Res. 2020 May;40(5):2715-2724
pubmed: 32366417
Cell Commun Signal. 2018 Sep 4;16(1):54
pubmed: 30180849
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7
pubmed: 24277834
Cells. 2020 Apr 25;9(5):
pubmed: 32344898
Cancers (Basel). 2020 May 19;12(5):
pubmed: 32438733
Cancer Res. 2015 Aug 1;75(15):2969-74
pubmed: 26180080
Exp Cell Res. 2018 Jul 15;368(2):137-146
pubmed: 29674112
Cancer Res. 2016 Jul 15;76(14):4124-35
pubmed: 27216177
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Cancer Discov. 2021 Apr;11(4):933-959
pubmed: 33811125
J Natl Cancer Inst. 2012 Oct 3;104(19):1470-84
pubmed: 22984202
J Chemother. 2019 Nov - Dec;31(7-8):408-418
pubmed: 31724495
Am J Cancer Res. 2020 Nov 01;10(11):3622-3643
pubmed: 33294258
Cancer Res. 2014 Jun 1;74(11):2999-3010
pubmed: 24710408
Cell Rep. 2018 Nov 20;25(8):2177-2191.e7
pubmed: 30463014
J Hematol Oncol. 2019 Sep 23;12(1):101
pubmed: 31547836
Hepatology. 2015 Aug;62(2):481-95
pubmed: 25833323
Biochem Biophys Res Commun. 2017 Dec 2;493(4):1464-1470
pubmed: 28988111
J Cell Biochem. 2004 May 1;92(1):178-88
pubmed: 15095413
Annu Rev Physiol. 2017 Feb 10;79:541-566
pubmed: 27813830
Cancer Biol Ther. 2020;21(3):258-268
pubmed: 31825725
J Pathol. 2016 Oct;240(2):211-23
pubmed: 27425378
Cancer Metastasis Rev. 2019 Sep;38(3):483-492
pubmed: 31734763
J Hematol Oncol. 2019 May 29;12(1):53
pubmed: 31142326
Mol Cancer Ther. 2013 Nov;12(11):2378-88
pubmed: 23990114
J Thromb Haemost. 2008 Sep;6(9):1558-64
pubmed: 18624980
J Clin Invest. 2021 Mar 15;131(6):
pubmed: 33720045
Cell Commun Signal. 2019 Jun 6;17(1):58
pubmed: 31170987
Biol Pharm Bull. 2009 Apr;32(4):573-7
pubmed: 19336886
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Cancers (Basel). 2021 Feb 18;13(4):
pubmed: 33670717
J Cell Biochem. 2018 Nov;119(11):9419-9432
pubmed: 30015355
JCI Insight. 2018 Oct 18;3(20):
pubmed: 30333314
Cancer Biol Ther. 2015;16(2):253-60
pubmed: 25587663
Cell Death Dis. 2018 Jul 9;9(7):759
pubmed: 29988148
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Clin Cancer Res. 2018 Nov 1;24(21):5407-5421
pubmed: 29959142
Gut. 2015 Oct;64(10):1593-604
pubmed: 25608525
J Cell Mol Med. 2019 Apr;23(4):2984-2994
pubmed: 30734495
Cancers (Basel). 2020 Dec 21;12(12):
pubmed: 33371368
Am J Respir Crit Care Med. 2003 Jun 15;167(12):1676-86
pubmed: 12626353